TriSalus Life Sciences, Inc. (TLSI)
Automate Your Wheel Strategy on TLSI
With Tiblio's Option Bot, you can configure your own wheel strategy including TLSI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TLSI
- Rev/Share 1.1267
- Book/Share -1.2048
- PB -4.5733
- Debt/Equity -0.9635
- CurrentRatio 2.1353
- ROIC -1.8739
- MktCap 208492890.0
- FreeCF/Share -1.2447
- PFCF -5.8717
- PE -5.7758
- Debt/Assets 1.1569
- DivYield 0
- ROE 1.0382
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | TLSI | Lake Street | -- | Buy | -- | -- | Feb. 13, 2025 |
| Initiation | TLSI | Cantor Fitzgerald | -- | Overweight | -- | $10 | Dec. 17, 2024 |
| Initiation | TLSI | Oppenheimer | -- | Outperform | -- | $10 | Sept. 16, 2024 |
News
TriSalus Life Sciences, Inc. (TLSI) Q1 2025 Earnings Conference Call Transcript
Published: May 15, 2025 by: Seeking Alpha
Sentiment: Neutral
TriSalus Life Sciences, Inc. (TLSI) Q1 2025 Earnings Conference Call Transcript
Read More
TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Negative
TriSalus Life Sciences, Inc. (TLSI) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.54 per share a year ago.
Read More
TriSalus Life Sciences, Inc. (TLSI) Soars 6.6%: Is Further Upside Left in the Stock?
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Positive
TriSalus Life Sciences, Inc. (TLSI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Read More
TriSalus Life Sciences, Inc. (TLSI) Q4 2024 Earnings Call Transcript
Published: March 27, 2025 by: Seeking Alpha
Sentiment: Neutral
TriSalus Life Sciences, Inc. (NASDAQ:TLSI ) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Company Participants Jeremy Feffer - Managing Director, LifeSci Advisors Mary Szela - President & Chief Executive Officer James Young - Chief Financial Officer Richard Marshall - Medical Director Conference Call Participants Carl Burns - Northland Capital Markets Justin Walsh - JonesTrading Frank Takkinen - Lake Street Capital Markets Suraj Kalia - Oppenheimer & Company William Plovanic - Canaccord Genuity Operator Good morning, and welcome to TriSalus Life Sciences Fourth Quarter and Full Year 2024 Earnings Conference Call. Currently, all participants are in a …
Read More
About TriSalus Life Sciences, Inc. (TLSI)
- IPO Date 2021-02-08
- Website https://trisaluslifesci.com
- Industry Medical - Devices
- CEO Ms. Mary T. Szela B.S.N., M.B.A.
- Employees 110